Burney Co. Acquires 4,912 Shares of Exelixis, Inc. $EXEL

Burney Co. increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 406,128 shares of the biotechnology company’s stock after purchasing an additional 4,912 shares during the quarter. Burney Co. owned approximately 0.15% of Exelixis worth $17,900,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hemington Wealth Management raised its position in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 522 shares during the period. Byrne Asset Management LLC grew its stake in Exelixis by 129.0% during the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 400 shares in the last quarter. Family Legacy Financial Solutions LLC purchased a new position in Exelixis during the second quarter valued at approximately $33,000. Costello Asset Management INC bought a new position in shares of Exelixis in the 1st quarter worth $39,000. Finally, Harbour Investments Inc. increased its holdings in shares of Exelixis by 900.0% in the 1st quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company’s stock worth $41,000 after buying an additional 990 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EXEL. Zacks Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. HC Wainwright decreased their price objective on shares of Exelixis from $53.00 to $46.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a report on Tuesday, October 21st. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Tuesday, July 29th. Finally, Leerink Partnrs upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $44.53.

Exelixis Trading Down 0.7%

Shares of EXEL opened at $38.67 on Monday. The firm has a market capitalization of $10.41 billion, a P/E ratio of 18.59, a P/E/G ratio of 0.79 and a beta of 0.38. Exelixis, Inc. has a 12-month low of $31.90 and a 12-month high of $49.62. The firm has a fifty day moving average price of $38.81 and a 200-day moving average price of $40.28.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.